137 related articles for article (PubMed ID: 11855558)
1. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.
Debernardi-Venon W; Barletti C; Alessandria C; Marzano A; Baronio M; Todros L; Saracco G; Repici A; Rizzetto M
Dig Dis Sci; 2002 Feb; 47(2):401-4. PubMed ID: 11855558
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
Schepke M; Werner E; Biecker E; Schiedermaier P; Heller J; Neef M; Stoffel-Wagner B; Hofer U; Caselmann WH; Sauerbruch T
Gastroenterology; 2001 Aug; 121(2):389-95. PubMed ID: 11487548
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study.
Venon WD; Baronio M; Leone N; Rolfo E; Fadda M; Barletti C; Todros L; Saracco G; Rizzetto M
J Hepatol; 2003 Apr; 38(4):455-60. PubMed ID: 12663237
[TBL] [Abstract][Full Text] [Related]
4. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
Schepke M; Wiest R; Flacke S; Heller J; Stoffel-Wagner B; Herold T; Ghauri M; Sauerbruch T
Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
[TBL] [Abstract][Full Text] [Related]
6. Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
Pouleur HG
Am J Hypertens; 1997 Dec; 10(12 Pt 2):318S-324S. PubMed ID: 9438776
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis.
Tripathi D; Therapondos G; Lui HF; Johnston N; Webb DJ; Hayes PC
Am J Gastroenterol; 2004 Feb; 99(2):390-4. PubMed ID: 15046234
[TBL] [Abstract][Full Text] [Related]
8. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
[TBL] [Abstract][Full Text] [Related]
10. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
Chrysant SG; Neutel JM; Ferdinand KC;
J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
[TBL] [Abstract][Full Text] [Related]
11. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
[TBL] [Abstract][Full Text] [Related]
12. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
Man in't Veld AJ
J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
[TBL] [Abstract][Full Text] [Related]
13. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
[TBL] [Abstract][Full Text] [Related]
14. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
Agasti AK; Mahajan AU; Phadke AY; Nathani PJ; Sawant P
J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
Franscini LM; Von Vigier RO; Pfister R; Casaulta-Aebischer C; Fossali E; Bianchetti MG
Am J Hypertens; 2002 Dec; 15(12):1057-63. PubMed ID: 12460701
[TBL] [Abstract][Full Text] [Related]
16. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Schneider AW; Kalk JF; Klein CP
Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K
Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596
[TBL] [Abstract][Full Text] [Related]
18. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
[TBL] [Abstract][Full Text] [Related]
19. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.
Kim JH; Kim JM; Cho YZ; Na JH; Kim HS; Kim HA; Kang HW; Baik SK; Kwon SO; Cha SH; Kim YJ; Kim MY
Clin Mol Hepatol; 2014 Dec; 20(4):376-83. PubMed ID: 25548744
[TBL] [Abstract][Full Text] [Related]
20. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Neutel JM; Germino FW; Smith D
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
